News Generic drugmaker Hikma pledges $1bn in US investment With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.
News Could a Novo error set up early GLP-1 generics in Canada? Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
News Jazz pays $145m to resolve Xyrem antitrust disputes Jazz Pharma has offered to pay $145m to settle claims it paid to prevent generic versions of its narcolepsy drug Xyrem from reaching the US market.
News Pharma tariffs "will hurt US consumers most of all" If pharmaceuticals are included in President Trump's 'Liberation Day' tariffs, it is US consumers who will suffer the most, says a new report.
News FDA approves first generics of anticoagulant Xarelto The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto.
News Trump tariffs 'would strain the pharma supply chain' Pharma organisations in the US have said that Trump's tariffs plan could drive up the cost of generics, block supply chains and worsen drug shortages.
Oncology Liver cancer diagnostic gets FDA breakthrough status, with P... Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face